## CITATION REPORT List of articles citing

Hydroxychloroquine use and decreased risk of diabetes in rheumatoid arthritis patients

DOI: 10.1097/rhu.0b013e318214b6b5 Journal of Clinical Rheumatology, 2011, 17, 115-20.

Source: https://exaly.com/paper-pdf/50710640/citation-report.pdf

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
65	Pleiotropic effects of inflammasome modulation in chronic gout and associated comorbidities: potential therapeutic implications. <i>International Journal of Clinical Rheumatology</i> , <b>2011</b> , 6, 669-676	1.5	2
64	Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2012</b> , 7, 934-42	6.9	99
63	A systematic review of validated methods for identifying patients with rheumatoid arthritis using administrative or claims data. <i>Vaccine</i> , <b>2013</b> , 31 Suppl 10, K41-61	4.1	65
62	Multifaceted effects of hydroxychloroquine in human disease. <i>Seminars in Arthritis and Rheumatism</i> , <b>2013</b> , 43, 264-72	5.3	88
61	Rheumatic manifestations of endocrine disease. Current Opinion in Rheumatology, 2013, 25, 37-43	5.3	11
60	Effect of hydroxychloroquine on the lipid profile of patients with Sjgren syndrome. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 902-8	4.1	16
59	A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , <b>2014</b> , 5, 77-85	4.5	52
58	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 492-50	ე <del>ვ</del> .4	1487
57	Re: Pareek A, Chandurkar N, Thomas N, et al. Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone. Curr Med Res Opin 2014;30:1257-66. <i>Current Medical Research and Opinion</i> , <b>2015</b> , 31, 1087-92	2.5	
56	Risk of Incident Diabetes Mellitus Associated With the Dosage and Duration of Oral Glucocorticoid Therapy in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , <b>2016</b> , 68, 1089-98	9.5	48
55	Cardiovascular disease in rheumatoid arthritis: Current perspectives on assessing and mitigating risk in clinical practice. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2015</b> , 29, 597-613	5.3	20
54	Considerations on treatment recommendations for rheumatoid arthritis. <i>Reumatologla Claica</i> , <b>2015</b> , 11, 193-5	0.9	2
53	Antidiabetogenic effects of hydroxychloroquine on insulin sensitivity and beta cell function: a randomised trial. <i>Diabetologia</i> , <b>2015</b> , 58, 2336-43	10.3	62
52	Considerations on treatment recommendations for rheumatoid arthritis. <i>Reumatologla Claica</i> (English Edition), <b>2015</b> , 11, 193-195	0.1	
51	Should very low doses of hydroxychloroquine and quinacrine be employed in combination for long-term maintenance of remission in systemic lupus to reduce the risk of ocular toxicity?. <i>Current Opinion in Rheumatology</i> , <b>2015</b> , 27, 213-5	5.3	6
50	The marketing of unproven drugs for diabetes and dyslipidaemia in India. <i>Lancet Diabetes and Endocrinology,the</i> , <b>2015</b> , 3, 758-60	18.1	8
49	Treatment of rheumatoid arthritis: Unraveling the conundrum. <i>Journal of Autoimmunity</i> , <b>2015</b> , 65, 1-18	15.5	73

## (2019-2015)

48	randomized, double-blind comparison with atorvastatin alone among Indian patients with dyslipidemia. <i>Current Medical Research and Opinion</i> , <b>2015</b> , 31, 2105-17	2.5	22
47	Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2017</b> , 3, 92-97	6.4	22
46	Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 952-7	2.4	153
45	Immune-Modulating Therapy for Rheumatologic Disease: Implications for Patients with Diabetes. <i>Current Diabetes Reports</i> , <b>2016</b> , 16, 91	5.6	3
44	Use of Tumor Necrosis Factor-Alpha Inhibitors in Children and Young Adults With Juvenile Idiopathic Arthritis or Rheumatoid Arthritis. <i>Pharmacotherapy</i> , <b>2016</b> , 36, 1201-1209	5.8	10
43	Hydroxychloroquine Use Is Associated With Decreased Incident Cardiovascular Events in Rheumatoid Arthritis Patients. <i>Journal of the American Heart Association</i> , <b>2016</b> , 5,	6	96
42	PDE5 Inhibitor Tadalafil and Hydroxychloroquine Cotreatment Provides Synergistic Protection against Type 2 Diabetes and Myocardial Infarction in Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2017</b> , 361, 29-38	4.7	5
41	Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 848-854	2.4	50
40	Statin therapy now more common than steroids in clinical practice. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, e18	2.4	
39	Prevalence of glucose intolerance in rheumatoid arthritis patients at a tertiary care centre in Haryana. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , <b>2017</b> , 11 Suppl 2, S1013-S101	6 <sup>8.9</sup>	3
38	Hydroxychloroquine: Looking into the Future. <i>Romanian Journal of Diabetes Nutrition and Metabolic Diseases</i> , <b>2017</b> , 24, 369-375	0.2	4
37	Association between use of disease-modifying antirheumatic drugs and diabetes in patients with ankylosing spondylitis, rheumatoid arthritis, or psoriasis/psoriatic arthritis: a nationwide, population-based cohort study of 84,989 patients. <i>Therapeutics and Clinical Risk Management</i> , <b>2017</b> ,	2.9	12
36	Hydroxychloroquine may be associated with reduced risk of coronary artery diseases in patients with rheumatoid arthritis: A nationwide population-based cohort study. <i>International Journal of Clinical Practice</i> , <b>2018</b> , 72, e13095	2.9	12
35	Revisiting Type 1 Diabetes as a Comorbidity in Patients with Juvenile Idiopathic Arthritis. <i>Journal of Pediatrics</i> , <b>2018</b> , 192, 6-7	3.6	4
34	Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 98-103	2.4	117
33	Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: a systematic review and meta-analysis. <i>Drug Design, Development and Therapy,</i> <b>2018</b> , 12, 1685-1695	4.4	53
32	Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis. <i>PLoS ONE</i> , <b>2019</b> , 14, e02	150/459	22
31	Molecular signaling mechanisms of renal gluconeogenesis in nondiabetic and diabetic conditions. Journal of Cellular Physiology, <b>2019</b> , 234, 8134-8151	7	11

Hydroxychloroquine in diabetes and dyslipidaemia: primum non nocere. Diabetic Medicine, 2020, 37, 1404:4 405₄. 30 The association between the biological disease-modifying anti-rheumatic drugs and the incidence 29 10.2 of diabetes: A systematic review and meta-analysis. Pharmacological Research, 2020, 161, 105216 Risk of Incident Type 2 Diabetes Mellitus Among Patients With Rheumatoid Arthritis: A 28 6 4.7 Population-Based Cohort Study. Arthritis Care and Research, 2020, 72, 1248-1256 Incident diabetes associated with hydroxychloroquine, methotrexate, biologics and glucocorticoids in rheumatoid arthritis: A systematic review and meta-analysis. Seminars in Arthritis and Rheumatism 8 27 5.3 , **2020**, 50, 598-607 Antihyperglycemic properties of hydroxychloroquine in patients with diabetes: Risks and benefits 26 3.8 19 at the time of COVID-19 pandemic. Journal of Diabetes, 2020, 12, 659-667 Effect of methotrexate use on the development of type 2 diabetes in rheumatoid arthritis patients: 25 3.7 7 A systematic review and meta-analysis. PLoS ONE, 2020, 15, e0235637 Basal metabolic rate and Charlson Comorbidity Index are independent predictors of metabolic 2.9 2 24 syndrome in patients with rheumatoid arthritis. Joint Bone Spine, 2020, 87, 455-460 Cardiovascular Diseases and Rheumatology. 2021, 353-381 23 Repurposing New Use for Old Drug Chloroquine against Metabolic Syndrome: A Review on Animal 2.2 3.7 4 and Human Evidence. International Journal of Medical Sciences, 2021, 18, 2673-2688 [Safety aspects of the treatment with glucocorticoids for rheumatoid arthritis]. Zeitschrift Fur 1.9 Rheumatologie, **2021**, 80, 295-304 Association of Rheumatoid Arthritis with Diabetic Comorbidity: Correlating Accelerated Insulin 20 Resistance to Inflammatory Responses in Patients. Journal of Multidisciplinary Healthcare, 2021, 14, 809-820 Testing the Effects of Disease-Modifying Antirheumatic Drugs on Vascular Inflammation in 19 O Rheumatoid Arthritis: Rationale and Design of the TARGET Trial. ACR Open Rheumatology, 2021, 3, 371-380 Effects of Hydroxychloroquine on endOthelial function in eLDerly with sleep apnea (HOLD): study 18 2.8 O protocol for a randomized clinical trial. Trials, 2021, 22, 638 Antimalarial drugs (and lupus). 2021, 601-609 17 Unconventional secretion of FABP4 by endosomes and secretory lysosomes. Journal of Cell Biology, 16 7.3 41 2018, 217, 649-665 Effect of hydroxychloroguine on oxidative/nitrosative status and angiogenesis in endothelial cells 15 3.5 11 under high glucose condition. *BioImpacts*, **2017**, 7, 219-226 Rheumatoid arthritis: influence of inflammation and anti-inflammatory therapy on cardiovascular 14 0.4 O risk factors. Meditsinskiy Sovet, 2020, 32-44 Cardiovascular Risk of Synthetic, Non-Biologic Disease-Modifying Anti- Rheumatic Drugs (DMARDs). 13 3.3 Current Vascular Pharmacology, 2020, 18, 455-462

## CITATION REPORT

12	Real-World Clinical Effectiveness and Tolerability of Hydroxychloroquine 400 Mg in Uncontrolled Type 2 Diabetes Subjects who are not Willing to Initiate Insulin Therapy (HYQ-Real-World Study). <i>Current Diabetes Reviews</i> , <b>2019</b> , 15, 510-519	2.7	16
11	Blood glucose changes surrounding initiation of tumor-necrosis factor inhibitors and conventional disease-modifying anti-rheumatic drugs in veterans with rheumatoid arthritis. <i>World Journal of Diabetes</i> , <b>2018</b> , 9, 53-58	4.7	3
10	Nonimmunosuppressive disease-modifying antirheumatic drugs. <b>2015</b> , 434-442		1
9	Cutaneous Lupus. <b>2022</b> , 25-52		
8	Monitoring and Managing Cardiovascular Risk in Immune Mediated Inflammatory Diseases <i>Journal of Inflammation Research</i> , <b>2021</b> , 14, 6893-6906	4.8	1
7	Diabetes-Modifying Antirheumatic Drugs: The Roles of DMARDs as Glucose-Lowering Agents. <i>Medicina (Lithuania)</i> , <b>2022</b> , 58, 571	3.1	1
6	Drug monitoring in systemic lupus erythematosus Current Opinion in Pharmacology, 2022, 64, 102225	5.1	
5	Sjgren syndrome is a hidden contributor of macrovascular and microvascular complications in patients with type 2 diabetes.		
4	Treating diabetes with combination of phosphodiesterase 5 inhibitors and hydroxychloroquine possible prevention strategy for COVID-19?.		O
3	A PILOT STUDY ON EFFECT OF HYDROXYCHLOROQUINE IN GLYCEMIC CONTROL OF WOMEN WITH RHEUMATOID ARTHRITIS IN A TERTIARY CARE HOSPITAL, EASTERN ZONE OF INDIA. <b>2022</b> , 31-33		О
2	Association between Diabetes and Rheumatoid Arthritis: A Systematic Literature Review. <b>2022</b> , 16,		O
1	Hydroxychloroquine: Chemistry and Medicinal Applications. 2023, 106,		O